A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al (2017) IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127(8):2930–2940. https://doi.org/10.1172/JCI91190
Balch CM, Gershenwald JE, Soong S et al (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452–2459. https://doi.org/10.1200/JCO.2009.27.1627
Bol KF, Aarntzen EHJG, in’t Hout FEM et al (2016) Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology 5:1–8. https://doi.org/10.1080/2162402X.2015.1057673
Bonehill A, Tuyaerts S, Van Nuffel AMT et al (2008) Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16:1170–1180. https://doi.org/10.1038/mt.2008.77
Bonehill A, Van Nuffel AMT, Corthals J et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15:3366–3375. https://doi.org/10.1158/1078-0432.CCR-08-2982
Byrd DR, Sondak VK, Soong S et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206. https://doi.org/10.1200/jco.2009.23.4799
Carrasco J, Van Pel A, Neyns B et al (2014) Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 180:3585–3593. https://doi.org/10.4049/jimmunol.180.5.3585
Daud AI, Wolchok JD, Robert C et al (2016) Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 34:4102–4109. https://doi.org/10.1200/JCO.2016.67.2477
Eggermont AMM, Blank CU, Mandala M et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378:1789–1801. https://doi.org/10.1056/NEJMoa1802357
Eggermont AMM, Chiarion-Sileni V, Grob J-J et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375:1845–1855. https://doi.org/10.1056/NEJMoa1611299
Long GV, Hauschild A, Santinami M et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813–1823. https://doi.org/10.1056/nejmoa1708539
Markowicz S, Nowecki ZI, Rutkowski P et al (2012) Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. Med Oncol 29:2966–2977. https://doi.org/10.1007/s12032-012-0168-1
Mocellin S, Lens MB, Pasquali S et al (2013) Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd008955.pub2
Ollila DW (2006) Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol 7:919–924. https://doi.org/10.1016/S1470-2045(06)70938-X
Romano E, Scordo M, Dusza SW et al (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28:3042–3047. https://doi.org/10.1200/JCO.2009.26.2063
Van Nuffel AMT, Benteyn D, Wilgenhof S et al (2012) Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4 + and CD8 + T cells in melanoma patients. Mol Ther 20:1063–1074. https://doi.org/10.1038/mt.2012.11
Van Nuffel AMT, Benteyn D, Wilgenhof S et al (2012) Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 61:1033–1043. https://doi.org/10.1007/s00262-011-1176-2
Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824–1835. https://doi.org/10.1056/NEJMoa1709030
Wilgenhof S, Corthals J, Heirman C et al (2016) Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 34:1330–1338. https://doi.org/10.1200/JCO.2015.63.4121
Wilgenhof S, Corthals J, Van Nuffel AMT et al (2015) Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother 64:381–388. https://doi.org/10.1007/s00262-014-1642-8
Wilgenhof S, Van Nuffel AMT, Benteyn D et al (2013) A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol Off J Eur Soc Med Oncol 24:2686–2693. https://doi.org/10.1093/annonc/mdt245